Insight

Aug 19, 2024, 06:27

New research reveals why EGFR+ lung cancer treatments may fail over time – EGFR Positive UK

EGFR Positive UK shared a post on X about a recent paper by Claire Lailler et al. published in Oncogene.

“PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up”

Authors: Claire Lailler, Audrey Didelot, Simon Garinet, Hélène Blons, Sophie Mouillet-Richard et al.

New research reveals why EGFR+ lung cancer treatments may fail over time - EGFR Positive UK

“New research reveals why EGFR+ lung cancer treatments may fail over time: PrPC appears to play a crucial role in why some treatments stop working, potentially pointing the way to strategies to keep treatments effective longer and improve outcomes.”

Source: EGFR Positive UK/X

Audrey Didelot cancer Claire Lailler EGFR lung cancer EGFR Positive UK Hélène Blons Lung cancer OncoDaily oncogene Oncology Simon Garinet Sophie Mouillet-Richard

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity